查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1478594

類風濕性關節炎藥物的市場規模 - 按藥物類別、給藥途徑、銷售管道和分銷管道分類 - 區域前景、競爭策略和細分市場預測（截至 2033 年）

Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 234 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計2033年，全球類風濕性關節炎治療藥物市場規模將成長至787,184.2億日圓，複合年成長率為3.8%。

類風濕性關節炎是一種自體免疫疾病，人體的免疫系統會攻擊自身組織，包括關節。用於治療類風濕性關節炎的藥物稱為抗風濕藥物。所有年齡層的人都受到這種疾病的影響，但老年人最容易受到這種疾病的影響。類風濕性關節炎的症狀包括關節腫脹、僵硬、疼痛和不適。目前尚無治療類風濕性關節炎的既定治療方法。

2020 年 1 月 30 日，世界衛生組織 (WHO) 將 COVID-19 認定為全球突發公共衛生事件。 COVID-19 已影響全球約 210 個國家。根據《刺胳針風濕病學 2020》報導，類風濕性關節炎患者感染 COVID-19 可能會導致嚴重症狀。某些 DMARD，例如羥氯喹，通常用於治療類風濕性關節炎，但也正在研究作為潛在的 COVID-19 治療。

本報告調查了全球類風濕性關節炎治療藥物市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場/地區/主要國家的詳細分析、競爭狀況，我們編制了以下概況：主要企業。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 促進因素、抑制因素、機會與挑戰分析
  • COVID-19 對市場的影響

第5章 市場變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭狀況

  • 製造地、銷售區域、產品類型分佈
  • 併購、聯盟、產品發布、合作

第7章全球類類風濕性關節炎關節炎藥物市場：依藥物類別

  • 全球市場規模、佔有率和預測
  • 緩解疾病抗風濕藥物 (DMARD)
  • 非類固醇消炎劑(NSAID)
  • 皮質類固醇
  • 降尿酸藥
  • 其他

第8章全球類類風濕性關節炎關節炎藥物市場：途徑分類

  • 全球市場規模、佔有率和預測
  • 口服
  • 胃腸外的

第9章全球類類風濕性關節炎藥物市場：依銷售管道分類

  • 全球市場規模、佔有率和預測
  • 處方藥
  • 非處方藥

第10章全球類類風濕性關節炎關節炎藥物市場：依分銷管道分類

  • 全球市場規模、佔有率和預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章全球類類風濕性關節炎關節炎藥物市場預測

  • 市場規模/市場佔有率

第12章全球類風濕性關節炎藥物市場：按地區

  • 市場規模/市場佔有率趨勢/預測
  • 亞太地區
  • 歐洲
  • 中東/非洲
  • 北美洲
  • 拉丁美洲

第13章 公司簡介

  • AbbVie Inc.
  • Johnson & Johnson Innovative Medicine
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • 其他

第14章簡稱

第15章 參考鏈接

第16章結論

第17章 研究範圍

簡介目錄
Product Code: PHAR2406

Rheumatoid Arthritis Drugs Market Introduction and Overview

According to SPER market research, Rheumatoid Arthritis Drugs Market Size- By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033 state that the Global Rheumatoid Arthritis Drugs Market is predicted to reach 78718.42 million by 2033 with a CAGR of 3.8%.

Rheumatoid arthritis is an autoimmune disease that results in the body's immune system attacking its own tissues, including joints. This leads to edema and painful joint stiffness. A medication used to treat rheumatoid arthritis is known as an anti-rheumatic medication. All ages are affected by this ailment, albeit the elderly are most susceptible to it. Rheumatoid arthritis symptoms include swelling, stiffness, pain, and discomfort in the joints. Rheumatoid arthritis currently has no recognized treatment.

On January 30, 2020, the World Health Organization (WHO) deemed the COVID-19 pandemic a global public health emergency. Globally, COVID-19 has had an impact on around 210 countries. Patients with rheumatoid arthritis who also have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, such hydroxychloroquine, are being studied as possible COVID-19 therapies in addition to being often used to treat rheumatoid arthritis.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Segmentation

By Drug Class Type: Based on the Drug Class Type, Global Rheumatoid Arthritis Drugs Market is segmented as, Disease-modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others.

By Route of Administration: Based on the Route of Administration, Global Rheumatoid Arthritis Drugs Market is segmented as; Oral, Parenteral.

By Sales Channel: Based on the Sales Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Prescription-based Drugs, Over-the-counter Drugs.

By Distribution Channel: Based on the Distribution Channel, Global Rheumatoid Arthritis Drugs Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market

7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033

  • 7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
  • 7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
  • 7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • 7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.5. Corticosteroids
  • 7.6. Uric Acid Drugs
  • 7.7. Others

8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033

  • 8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
  • 8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
  • 8.3. Oral
  • 8.4. Parenteral

9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033

  • 9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
  • 9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
  • 9.3. Prescription-based Drugs
  • 9.4. Over-the-counter Drugs

10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033

  • 10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 10.3. Hospital Pharmacy
  • 10.4. Retail Pharmacy
  • 10.5. Online Pharmacy

11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)

  • 11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share

12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)

  • 12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
  • 12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Qatar
    • 12.5.4. South Africa
    • 12.5.5. Egypt
    • 12.5.6. Morocco
    • 12.5.7. Nigeria
    • 12.5.8. Rest of Middle-East and Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profile

  • 13.1. AbbVie Inc.
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Johnson & Johnson Innovative Medicine
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Amgen Inc.
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Pfizer Inc.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. Novartis AG
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Sanofi S.A.
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. F. Hoffmann-La Roche Ltd.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Merck & Co., Inc.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Bristol-Myers Squibb Company
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Eli Lilly and Company
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope